Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Background: metabolic dysfunction-associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N-terminal propeptide of collagen type 3 (PRO-C3) is a biomarker of advanced fibrosis in MAFLD and PRO-C3 may be involved in renal fibrosis. We aimed to use PRO-C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD).
Methods: a derivation and independent validation cohort of 750 and 129 Asian patients with biopsy-confirmed MAFLD were included. Serum PRO-C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis.
Results: the study included two Asian cohorts (n = 180 with MAFLD–CKD; mean-eGFR: 94.93 mL/min/1.73 m2; median-urinary albumin-to-creatinine ratio: 6.58 mg/mmol). PRO-C3 was associated with the severity of MAFLD-CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). A new non-invasive score (termed PERIOD) including PRO-C3 efficiently predicted MAFLD-CKD (AUROC = .842, 95% CI: .805–.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691–.893) with similar results in all patient subgroups. In the MAFLD–CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO-C3-based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836–.964).
Conclusions: the PERIOD score is helpful for accurately predicting the risk of MAFLD–CKD. PRO-C3 can also be used to assess liver fibrosis in people with MAFLD–CKD.
N-terminal propeptide of type 3 collagen, chronic kidney disease, liver fibrosis, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, risk prediction
1129-1141
Tang, Liang-Jie
586390dd-64da-4988-86e0-c3ea141cffc3
Sun, Dan-Qin
56d2d368-71df-400a-8a1d-a62afdce5771
Song, Sherlot Juan
6567e42e-2057-444f-97ab-29597ff4d056
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
May 2024
Tang, Liang-Jie
586390dd-64da-4988-86e0-c3ea141cffc3
Sun, Dan-Qin
56d2d368-71df-400a-8a1d-a62afdce5771
Song, Sherlot Juan
6567e42e-2057-444f-97ab-29597ff4d056
Byrne, Christopher D.
1370b997-cead-4229-83a7-53301ed2a43c
Tang, Liang-Jie, Sun, Dan-Qin and Song, Sherlot Juan
,
et al.
(2024)
Serum PRO-C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort.
Liver International, 44 (5), .
(doi:10.1111/liv.15878).
Abstract
Background: metabolic dysfunction-associated fatty liver disease (MAFLD) is an emerging risk factor for chronic kidney disease (CKD). N-terminal propeptide of collagen type 3 (PRO-C3) is a biomarker of advanced fibrosis in MAFLD and PRO-C3 may be involved in renal fibrosis. We aimed to use PRO-C3 measurements to generate a new algorithmic score to test the prediction of MAFLD with chronic kidney disease (MAFLD–CKD).
Methods: a derivation and independent validation cohort of 750 and 129 Asian patients with biopsy-confirmed MAFLD were included. Serum PRO-C3 concentration was measured and regression analyses were performed to examine associations with MAFLD–CKD. A derivative algorithm for MAFLD–CKD risk prediction was evaluated with receiver operator characteristic (ROC) curve analysis.
Results: the study included two Asian cohorts (n = 180 with MAFLD–CKD; mean-eGFR: 94.93 mL/min/1.73 m2; median-urinary albumin-to-creatinine ratio: 6.58 mg/mmol). PRO-C3 was associated with the severity of MAFLD-CKD and independently associated with MAFLD–CKD (adjusted odds ratio = 1.16, 95% confidence interval [CI]: 1.08–1.23, p < .001). A new non-invasive score (termed PERIOD) including PRO-C3 efficiently predicted MAFLD-CKD (AUROC = .842, 95% CI: .805–.875). Accuracy, specificity and negative predictive values were 80.2%, 85.1% and 88.4%, respectively. In the validation cohort, the PERIOD score had good diagnostic performance (AUROC = .807, 95% CI: .691–.893) with similar results in all patient subgroups. In the MAFLD–CKD subgroup, the accuracy for identifying advanced fibrosis was further improved by combining the PRO-C3-based ADAPT with the Agile 3+ scores (AUROC = .90, 95% CI: .836–.964).
Conclusions: the PERIOD score is helpful for accurately predicting the risk of MAFLD–CKD. PRO-C3 can also be used to assess liver fibrosis in people with MAFLD–CKD.
Text
Manuscript_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 1_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 2_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 3_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 4_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 5_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Supplementary Table 6_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Table 1_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Text
Table 2_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 1_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 2_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 3_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Figure 4_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Graphic abstract_R1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Supplementary Figure 1
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Image
Supplementary Figure 2
- Accepted Manuscript
Restricted to Repository staff only until 9 February 2025.
Request a copy
Show all 16 downloads.
More information
Accepted/In Press date: 9 February 2024
Published date: May 2024
Keywords:
N-terminal propeptide of type 3 collagen, chronic kidney disease, liver fibrosis, metabolic dysfunction-associated fatty liver disease, metabolic dysfunction-associated steatotic liver disease, risk prediction
Identifiers
Local EPrints ID: 487138
URI: http://eprints.soton.ac.uk/id/eprint/487138
ISSN: 1478-3223
PURE UUID: f7449166-91dc-47a9-bf77-dc9028a927f5
Catalogue record
Date deposited: 14 Feb 2024 17:38
Last modified: 22 May 2024 01:36
Export record
Altmetrics
Contributors
Author:
Liang-Jie Tang
Author:
Dan-Qin Sun
Author:
Sherlot Juan Song
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics